News Archive

Cantargia shows in-vivo proof of concept in malignant melanoma »
12-02-09

More attention on Cantargia in the internationally recognized magazine "BioCentury" »
12-01-31

ProNoxis has secured SEK 4.0 million in a new round of financing »
12-01-25

New rights issue in LU Bio February 2012 »
12-01-18

LUIS - LU Bio collaboration generates two new companies »
11-08-30

New investment in ProNoxis »
11-06-17

Attention on XImmune in BioCentury »
11-04-13

Cantargia builds power »
11-02-21

Continued progress in XImmune »
11-02-07

LU Bio acknowledged in high profile publication SciBX »
11-01-22

LU Bio sales of holdings »
10-12-08

Report on LU Bio portfolio company ProNoxis published in BioCentury »
10-10-07

LU Bio has decided to close the portfolio company Auril »
10-09-30

Article on Cantargia published in SciBX regarding “Homing in on CML stem cells“ »
10-09-17

LU Bio and Bio-Medisinsk Innovasjon AS in Oslo starts new co-operation »
10-09-13

LU Bio portfolio company Cantargia in the newsroom »
10-08-31

LU Bio dispose Oncorel holdings »
10-04-14

LU Bio portfolio company XImmune in the newsroom »
10-03-25

Dermagen reports successful phase I/IIa clinical trial »
09-12-02

LU Bioscience increases position in ProNoxis »
09-11-12

Successful findings from our portfolio company Auril noticed »
09-09-07

New investment dealing with temperature reduction in patients »
09-06-23

LU Bio announces a continued investment in Cytoguide ApS »
09-06-02

New portfolio company ProNoxis established »
09-06-01

Open seminar at Biomedical Center, Lund University, on March 25 »
09-03-15

Cantargia builds power

Share

| Print |

Tell a colleague

Tell a colleague about this

Your name

Recipient E-mail

Share this page

Google Bookmarks

Cantargia builds power and has secured financing up to the pre-clinical phase, strengthened the Board and recruited a CEO.

Click here to read the press release

+46 (0)46 286 48 20
info@lubio.se

Ideon, Alfa 5
SE 223 70 Lund, Sweden

Lund University Bioscience AB

Contact us